ADMA Biologics Announces Third Quarter 2025 Financial Results and Provides Business Update

3Q 2025 Total Revenue of $134.2 Million, a 12% YoY Increase 

3Q 2025 GAAP Net Income of $36.4 Million, a 1% YoY Increase

3Q 2025 Adjusted EBITDA⁽¹⁾ of $58.7 Million, a 29% YoY Increase

Read more at globenewswire.com